Mesoblast set for Asian launch
Monday, 16 February, 2009
Melbourne biotech Mesoblast has signed a collaborative program with Singapore’s Parkway Group Healthcare to trial its cartilage stem cell product RepliCart.
RepliCart is aimed at preventing or treating osteoarthritis of the knee, both in the elderly and following knee reconstruction surgery.
Last month, Mesoblast announced it was beginning Phase II trials of RepliCart in people under 40 who had undergone anterior cruciate ligament surgery
The agreement with Parkway Group Healthcare, which operates 15 private hospitals in Asia, involves a single-injection safety and efficacy trial at Parkway’s Clinical Centre of Excellence in Singapore.
Mesoblast said further trials were planned for additional clinical indications.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
